Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: review decision

The Institute was proposing that TA261 and TA287 should be transferred to the ‘static guidance’ list.

Only one response was received during the consultation, and this was supportive of the proposal. As a result, the Institute will proceed with the original proposal and both TA261 and TA287 will move to the ‘static guidance'.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

This page was last updated: 26 June 2015